{
  "subset": "indication",
  "disease": "Generalised pustular psoriasis",
  "relation": "indication",
  "gold_drugs": [
    "certolizumab pegol",
    "spesolimab"
  ],
  "seeds_initial": [
    "Infliximab",
    "Adalimumab",
    "Apremilast",
    "Acitretin",
    "Methotrexate",
    "Cyclosporine",
    "Etanercept",
    "Vedolizumab",
    "Ustekinumab",
    "Secukinumab",
    "Brodalumab",
    "Tazarotene"
  ],
  "seed_history": [
    [
      "Infliximab",
      "Adalimumab",
      "Apremilast",
      "Acitretin",
      "Methotrexate",
      "Cyclosporine",
      "Etanercept",
      "Vedolizumab",
      "Ustekinumab",
      "Secukinumab",
      "Brodalumab",
      "Tazarotene"
    ],
    [
      "Acitretin",
      "Adalimumab",
      "Apremilast",
      "Brodalumab",
      "Etanercept",
      "Guselkumab",
      "Infliximab",
      "Ixekizumab",
      "Methotrexate",
      "Secukinumab",
      "Tildrakizumab",
      "Ustekinumab"
    ],
    [
      "Acitretin",
      "Adalimumab",
      "Etanercept",
      "Infliximab",
      "Secukinumab",
      "Ixekizumab",
      "Austedo",
      "Methotrexate",
      "Cyclosporine",
      "Tildrakizumab",
      "Brodalumab",
      "Ustekinumab"
    ]
  ],
  "final_report": {
    "final_recommendations": [
      {
        "hypothesis_id": "H1",
        "candidate": {
          "id": "drug_acitretin",
          "name": "Acitretin"
        },
        "score": 0.48,
        "graph_snapshot_ref": "GE_H1_round4",
        "key_assumptions": [
          "Acitretin作用于IL-17A并已被用于治疗",
          "潜在副作用风险需进一步验证"
        ],
        "caveats": [
          "副作用风险较高，长期效果不明确"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H2",
        "candidate": {
          "id": "drug_adalimumab",
          "name": "Adalimumab"
        },
        "score": 0.48,
        "graph_snapshot_ref": "GE_H2_round4",
        "key_assumptions": [
          "Adalimumab靶向TNF-alpha以减少炎症",
          "主要副作用风险需评估"
        ],
        "caveats": [
          "长期疗效与安全性需进一步验证"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H3",
        "candidate": {
          "id": "drug_etanercept",
          "name": "Etanercept"
        },
        "score": 0.48,
        "graph_snapshot_ref": "GE_H3_round4",
        "key_assumptions": [
          "Etanercept靶向TNF-alpha并用于治疗此病",
          "副作用风险是否可接受需确认"
        ],
        "caveats": [
          "疗效尚需更多数据支持"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H4",
        "candidate": {
          "id": "drug_infliximab",
          "name": "Infliximab"
        },
        "score": 0.48,
        "graph_snapshot_ref": "GE_H4_round4",
        "key_assumptions": [
          "Infliximab通过抑制TNF-alpha发挥作用",
          "与潜在副作用相关的风险需评估"
        ],
        "caveats": [
          "需进一步验证使用安全性"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H5",
        "candidate": {
          "id": "drug_secukinumab",
          "name": "Secukinumab"
        },
        "score": 0.48,
        "graph_snapshot_ref": "GE_H5_round4",
        "key_assumptions": [
          "Secukinumab靶向IL-17A并显示帮助",
          "副作用风险需明确"
        ],
        "caveats": [
          "疗效与安全性待进一步解析"
        ],
        "confidence": "medium"
      }
    ],
    "audit_report": {
      "decisive_graph_motifs": [
        {
          "pattern": "Drug→Target→Pathway→Disease",
          "reason": "主要候选药物靶向关键病理途径"
        }
      ],
      "remaining_gaps": [
        "副作用风险的具体评估",
        "长期疗效数据不足"
      ]
    },
    "seed_retrospective": {
      "batches": [
        {
          "round": 1,
          "seeds": [
            "A",
            "B",
            "C",
            "D"
          ],
          "impact_summary": "帮助识别出有效的靶点"
        }
      ],
      "lessons": [
        "需优先关注副作用风险的研究",
        "靶向IL-17A的药物需具备明确的有效性和安全性数据"
      ]
    },
    "prompt_patches": [],
    "heuristics": []
  },
  "experience_used": true,
  "explorer_prompt": "List drugs that could be indicated for the rare disease 'Generalised pustular psoriasis'. Return only names.\n\n# Prior guidance for Explorer:\n- 聚焦针对特定表型的药物机理和效果，避免不必要的资源浪费\n\n# Heuristics:\n- When 一般性药物反应: then 关注相关通路与表型适应性，评估效果\n- When 疗效数据缺乏: then 需要结合已有的案例或试验结果进行评估"
}